BC Cancer Agency

What BC Cancer Agency does

BC Cancer is a publicly funded provincial cancer control program operated under the Provincial Health Services Authority (PHSA), a Crown corporation of the Government of British Columbia. Founded in 1935 (originally as the British Columbia Cancer Foundation) and headquartered in Vancouver, the organization serves British Columbia residents through six regional cancer centres in Vancouver, Victoria, Kelowna, Surrey, Abbotsford, and Prince George, covering the full spectrum of cancer care from prevention and screening through diagnosis, treatment, research, education, and supportive and palliative care.

Core clinical services include radiation therapy (External Beam Radiation Therapy and Brachytherapy, including first-in-Canada 3D-printed applicators at Kelowna), systemic therapy (chemotherapy and immunotherapy including Chimeric Antigen Receptor (CAR) T-cell therapy), population-based screening for breast, cervical, colon, and lung cancers, hereditary cancer services, and the Indigenous Cancer Control program. Underlying technology platforms include Personalized OncoGenomics (POG) for genomic-driven treatment selection, a PET Cyclotron and Radiopharmacy Facility for molecular imaging, public-sector CAR-T manufacturing (the first in Canada), and the BC Cancer Statistics Online Dashboard for province-wide cancer surveillance and projections.

The business model is publicly funded: all covered clinical services are delivered at no direct cost to eligible BC residents under the Medical Services Plan, with operational funding flowing from the BC Ministry of Health via PHSA. Research is supplemented by competitive grants from the Canadian Cancer Society, CIHR, and other agencies, plus co-funded programs with industry partners such as AstraZeneca Canada and the Leukemia & Lymphoma Society of Canada. Customer segments include cancer patients, the general population eligible for screening, adolescents and young adults (AYA), Indigenous peoples, and health professionals. The organization's research pipeline has produced at least 10 spin-off companies and contributed to seven oncology drugs reaching patients worldwide, including a first-in-Canada treatment for biliary tract cancer.

Name

BC Cancer Agency

Legal name

Provincial Health Services Authority

Website

https://bccancer.bc.ca

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

BC Cancer is a publicly funded provincial cancer control program operating six regional cancer centres across British Columbia, delivering prevention, screening, diagnosis, treatment, research, and supportive care to BC residents.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Hospitals (8060), Biological Products, (No Disgnostic Substances) (2836), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Medical Oncology (HLAKAFAB)

Keywords

• Cancer care services
• Oncology treatment
• Cancer screening programs
• Radiation therapy
• Clinical research

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices6 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Publicly Funded Healthcare Services: BC Cancer operates as a program under the Provincial Health Services Authority (PHSA), a Crown corporation of the Government of British Columbia. All clinical services are publicly funded through provincial healthcare budgets and do not charge patients directly for covered services. The organization receives operational funding from the BC Ministry of Health.
2. Research Grants and External Funding: BC Cancer researchers receive competitive grant funding from external bodies including the Canadian Cancer Society, Canadian Institutes of Health Research (CIHR), and other national and international funding agencies to support specific research programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

BC Cancer is a publicly funded provincial cancer control program that delivers the full continuum of cancer care — prevention, population-based screening (breast, cervical, colon, lung), diagnosis, multimodal treatment including radiation therapy (with first-in-Canada 3D-printed brachytherapy), chemotherapy, immunotherapy and CAR-T cell therapy, supportive/palliative care, and clinical research — through six regional cancer centres across British Columbia, all operated under the Provincial Health Services Authority.

Product overview

BC Cancer is a comprehensive provincial cancer control program operated by the Provincial Health Services Authority (PHSA) that provides the full spectrum of cancer care from prevention, screening, diagnosis, and treatment to research, education, supportive and palliative care across British Columbia. The organization operates six regional cancer centres (Abbotsford, Kelowna, Prince George, Surrey, Vancouver, Victoria) and offers core services including Radiation Therapy (External Beam and Brachytherapy with innovative 3D printing technology), Systemic Therapy/Chemotherapy with Immunotherapy and CAR-T Cell Therapy, Cancer Screening Programs (breast, cervical, colon, lung), Hereditary Cancer Program, Indigenous Cancer Control, and Supportive Care. Additional key offerings include the BC Cancer Statistics Online Dashboard for analytics, Clinical Trials Program across all centres, Personalized OncoGenomics for genomic analysis, and the Cancer Drug Manual for health professionals. The organization was the first in Canada to launch a provincial lung cancer screening program and manufacture CAR T-cell therapies, with seven oncology drugs originating in BC reaching patients worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• BC Cancer Screening: Population-based screening programs for breast, cervical, colon and lung cancer in British Columbia.
• Deeley Research Centre
• Personalized OncoGenomics

Products and services

• Cancer Screening Programs

Quantifiable outcome

• At least 10 companies have emerged as spin-offs from BC Cancer's research activities.
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Institut PasteurcoreStrategic or Co-development Partner · 5 March 2026International research collaborator on the UPFront project studying ultra-processed foods and colorectal cancer risk. Institut Pasteur is partnered alongside Université Paris Cité as international partners on this multi-provincial Canadian research team.
• Université Paris CitécoreStrategic or Co-development Partner · 5 March 2026International research collaborator on the UPFront project investigating ultra-processed food consumption and colorectal cancer risk. Part of a multi-provincial Canadian team including BC Cancer researchers, alongside Institut Pasteur.
• Canadian Partnership for Tomorrow's Health (CanPan)coreStrategic or Co-development Partner · 5 March 2026The UPFront project uses dietary and biospecimen data from the HEAL and CHARM studies embedded within the Canadian Partnership for Tomorrow's Health, a national population health research platform, to study diet-cancer relationships.
• AstraZeneca CanadaminorStrategic or Co-development Partner · 6 November 2025Co-funder with the Leukemia & Lymphoma Society of Canada of the 2025 Operating Grants in Blood Cancer, a research funding program supporting two blood cancer research projects in Canada.
• Leukemia & Lymphoma Society of CanadaminorStrategic or Co-development Partner · 6 November 2025Co-administering partner with AstraZeneca Canada of the 2025 Operating Grants in Blood Cancer funding program. The grant received 43 applications and supports leukemia biomarker research and gene editing tools for B-cell lymphoma development.
• Indigenous Cancer Control (Strategy with First Nations Health Authority and Métis Nation BC)coreStrategic or Co-development PartnerBC Cancer's Indigenous Cancer Control program works with the First Nations Health Authority, Métis Nation BC, and other Indigenous partners to deliver culturally safe, trauma-informed cancer care and improve Indigenous cancer journeys in BC.
• Provincial Health Services Authority (PHSA)coreStrategic or Co-development PartnerBC Cancer is a program under the Provincial Health Services Authority, a Crown corporation of the Government of British Columbia. PHSA provides province-wide health services and administrative infrastructure, with BC Cancer serving as the provincial cancer control program.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ontario Health (Cancer Care Ontario): Ontario's provincial cancer control agency, operating cancer centres and screening programs across Canada's most populous province. Most directly comparable as a publicly funded, government-mandated cancer control program serving a single province.
• Alberta Health Services – Cancer Care Alberta: Provincial cancer control program for Alberta, operating multiple cancer centres and providing population-based screening. Comparable as another Canadian province-wide public cancer agency with regional centre delivery.
• Saskatchewan Cancer Agency: Provincial cancer agency responsible for cancer care delivery across Saskatchewan. Similar public-agency model, smaller scale, multi-site delivery, comparable provincial mandate.
• Cancer Care Manitoba: Manitoba's provincial cancer program providing treatment, screening, and research. Closely comparable in scope, governance, and provincial single-payer model.

Broad incumbents

• Princess Margaret Cancer Centre (University Health Network): One of Canada's largest comprehensive cancer research and treatment centres, part of UHN in Toronto. Comparable in research intensity and CAR-T/cell therapy work, but operates as a single hospital within a multi-hospital network.
• MD Anderson Cancer Center: Global leader in oncology research and treatment based in Houston, Texas. Comparable in combining clinical care with research and clinical trials, but vastly larger scale with international patient draw.
• Memorial Sloan Kettering Cancer Center: US-based comprehensive cancer centre with strong research and CAR-T/cell therapy programs. Comparable as a comprehensive clinical-research oncology institution; much larger scale and private-pay mix.
• Fred Hutchinson Cancer Center: US-based cancer research and treatment centre with deep CAR-T and immunotherapy research heritage. Comparable in research-driven innovation model, particularly in cellular immunotherapy and translational genomics.

Others

• Canadian Cancer Society: National charitable funder of cancer research and patient support in Canada. Not a competitor but a key funding partner for BC Cancer researchers and a co-funder of programs like the UPFront project.
• National Cancer Institute (NCI): US federal agency leading cancer research and designated Comprehensive Cancer Centre program. Indirectly comparable as the institutional framework within which US peers operate; informs how BC Cancer benchmarks against national cancer strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/bccancer_agency
• Facebookfacebook.com/sharer.php?u=https://www.bccancer.bc.ca
• LinkedInlinkedin.com/company/bc-cancer
• Pinterestpinterest.com/pin/create/button/?url=https://www.bccancer.bc.ca/&description=BC%20Cancer%20-%20

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BC Cancer Agency